Biosimilar competition is expanding into high-value biologic markets, driven by rapid FDA approvals. However, patent expiry alone does not guarantee commercial success.
Market viability depends on reference product value, competition, physician switching behavior, and favorable pricing and reimbursement.
For pharma manufacturers, the critical question is whether a biosimilar can capture sufficient market share quickly enough to justify entry.
How Nexdigm Identifies Where Biosimilars Can Gain Share
Nexdigm approaches the opportunity from the market backwards.
Instead of starting with a list of biologics approaching loss of exclusivity, the assessment asks whether each molecule has the conditions required for commercially viable substitution.
That means looking at:
- Reference-product value: Sales, patient volume, treatment duration and growth
- Exclusivity: Patent and regulatory timelines and likely entry windows
- Competition: Existing biosimilars, development pipelines and expected entrants
- Adoption: Physician familiarity, switching behaviour and payer influence
- Economics: Price potential, expected share and competitive pressure
A large reference product can still be unattractive if development costs are high or several competitors are preparing to enter simultaneously.
Patent Expiry Opens the Door. It Does Not Guarantee Share.
The number of biologics approaching exclusivity loss is growing, but the pipeline is uneven. FDA reported in 2025 that 27% of high-value biologics generating more than $500 million in sales had no biosimilar development, despite their commercial potential.
That creates two very different situations.
A high-value biologic with no competing development may represent white space,
but it may also signal difficult manufacturing, uncertain returns or a relatively small addressable patient population.
A molecule with several biosimilars already in development offers proof that the market is commercially interesting, but it also signals stronger future competition.
Share Migration Depends on More Than Price
Price can encourage switching, but it does not determine who captures the volume.
European research found that cumulative savings from biosimilar competition had reached €56 billion by July 2024.
At the same time, its research shows substantial differences in physician awareness and adoption across specialties. In its osteoporosis research, 73% of surveyed healthcare providers had a positive or very positive view of biosimilars, while 33% cited lack of experience as a barrier to use.
This makes the adoption environment commercially important.
Nexdigm’s biosimilar assessment examines:
- Which physicians control prescribing
- Whether switching existing patients is accepted
- How hospitals determine formularies
- Whether payers encourage substitution
- Whether tenders determine purchasing
- How familiar providers are with the relevant biosimilar class
A product can therefore have a competitive price and still struggle to gain share if the decision-making environment is resistant to switching.
Biosimilar pricing is a balancing act.
FDA reports that biosimilar prices at launch have averaged about 50% below the reference product’s price at the time of launch.
For an entrant, however, the relevant calculation is not the headline discount.
It is the relationship between:
Price discount → switching → market share → revenue → sustainable return
That requires assessment of:
- Expected launch price
- Competitor discounts
- Number of market entrants
- Payer and tender incentives
- Manufacturing economics
- Expected achievable share
The strongest opportunity may therefore be a market where moderate pricing can unlock substantial switching, rather than one requiring extreme discounting to compete.
Regulation Is Also Changing the Entry Economics
The development environment itself is becoming more favourable. In March 2026, FDA proposed changes that could reduce certain biosimilar pharmacokinetic-study costs by up to 50%, or approximately $20 million, where scientifically justified.
That could change the attractiveness of molecules that previously appeared too expensive or complex to pursue.
For companies evaluating a portfolio, regulatory developments should therefore be treated as commercial inputs, not a compliance exercise performed after-market selection.
How Nexdigm Assesses Biosimilar Market Opportunity
Nexdigm can evaluate biosimilar opportunities through five connected dimensions:
- Reference Market Attractiveness
Size the reference biologic by sales, patient population, treatment volume, therapy area and growth to establish the value available for substitution. - Exclusivity & Competitive Pipeline
Map patent timelines, regulatory exclusivity, existing biosimilars and development pipelines to determine the timing and intensity of future competition. - Physician & Payer Adoption
Assess prescribing behaviour, switching willingness, physician familiarity, payer preferences, hospital formularies and procurement structures. - Pricing & Commercial Economics
Model price corridors, competitor discounts, expected market share and revenue potential to determine whether entry can generate sustainable returns. - Market Prioritization
Rank molecules and geographies according to reference-market value, entry feasibility, adoption readiness, competitive intensity and commercial attractiveness.
The result is a decision framework for determining which biosimilar markets merit development, licensing, acquisition or commercial investment.
Nexdigm’s Biosimilar Market Assessment
A global pharmaceutical company was evaluating 6 biosimilar candidates across 4 markets. Nexdigm compared reference-product sales, exclusivity timelines, competitor pipelines, physician adoption, reimbursement and pricing. Two candidates emerged as priorities, with market-specific launch strategies developed around payer access, physician engagement and competitive positioning.
Nexdigm’s biosimilar market opportunity analysis helps pharmaceutical companies bring these variables together before committing development or market-entry resources.
To take the next step, simply visit our Request a Consultation page and share your requirements with us.
Harsh Mittal
+91-8422857704
[email protected]